NCT03053362View on ClinicalTrials.gov

THINC-it Vortioxetine - Sensitivity to Change

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

158

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

August 8, 2018

Study Completion Date

August 8, 2018

Conditions

Major Depressive DisorderCognitive Change

Interventions

DRUG

Vortioxetine

Observing change in cognition using THINC-it tool in patients with MDD.

OTHER

THINC-it Tool

"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"

Trial Locations (1)

L5C 4E7

CRTCE/KJK Healthplex, Toronto

All Listed Sponsors

lead

Brain and Cognition Discovery Foundation

OTHER

NCT03053362 - THINC-it Vortioxetine - Sensitivity to Change | Biotech Hunter | Biotech Hunter